The CEO, CHAIRMAN OF BOARD of Celgene (NASDAQ: CELG) is Buying Shares

By Carrie Williams

Today, the CEO, CHAIRMAN OF BOARD of Celgene (NASDAQ: CELG), Mark Alles, bought shares of CELG for $99.78K.

See today’s analyst top recommended stocks >>

Based on Celgene’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.57 billion and quarterly net profit of $846 million. In comparison, last year the company earned revenue of $2.87 billion and had a net profit of $941 million. CELG’s market cap is $59.56B and the company has a P/E ratio of 23.11. Currently, Celgene has an average volume of 10.19M.

30 different firms, including Argus Research and Barclays, currently also have a Buy rating on the stock. Based on 21 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $117.13, reflecting a -31.7% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Hold CELG.

The insider sentiment on Celgene has been negative according to 66 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.